Skye Bioscience Files 8-K
Ticker: SKYE · Form: 8-K · Filed: Apr 3, 2024 · CIK: 1516551
Sentiment: neutral
Topics: disclosure, corporate-filing
TL;DR
Skye Bioscience dropped an 8-K, check the financials and disclosures.
AI Summary
Skye Bioscience, Inc. filed an 8-K on April 3, 2024, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc., is incorporated in Nevada and headquartered in San Diego, California.
Why It Matters
This filing provides important updates and disclosures for investors regarding Skye Bioscience's financial status and regulatory compliance.
Risk Assessment
Risk Level: low — This is a routine filing for corporate disclosures and does not inherently indicate new risks.
Key Players & Entities
- Skye Bioscience, Inc. (company) — Registrant
- Emerald Bioscience, Inc. (company) — Former company name
- Nemus Bioscience, Inc. (company) — Former company name
- April 3, 2024 (date) — Report date
- Nevada (jurisdiction) — State of incorporation
- San Diego, CA (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Skye Bioscience, Inc.?
The primary purpose is to provide a Regulation FD Disclosure and to file Financial Statements and Exhibits as of April 3, 2024.
When was the report filed and what is the earliest event date reported?
The report was filed on April 3, 2024, and the earliest event date reported is also April 3, 2024.
What are the previous names of Skye Bioscience, Inc.?
Skye Bioscience, Inc. was formerly known as Emerald Bioscience, Inc. and Nemus Bioscience, Inc.
In which state is Skye Bioscience, Inc. incorporated and what is its principal executive office address?
Skye Bioscience, Inc. is incorporated in Nevada and its principal executive offices are located at 11250 El Camino Real, Suite 100, San Diego, CA 92130.
What is the SIC code for Skye Bioscience, Inc.?
The Standard Industrial Classification (SIC) code for Skye Bioscience, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 699 words · 3 min read · ~2 pages · Grade level 12.9 · Accepted 2024-04-03 17:07:54
Key Financial Figures
- $5 million — e Company's compliance with the minimum $5 million stockholders' equity requirement for in
Filing Documents
- skye-20240403.htm (8-K) — 30KB
- a991_unauditedproformabala.htm (EX-99.1) — 51KB
- 0001516551-24-000052.txt ( ) — 199KB
- skye-20240403.xsd (EX-101.SCH) — 2KB
- skye-20240403_lab.xml (EX-101.LAB) — 20KB
- skye-20240403_pre.xml (EX-101.PRE) — 11KB
- skye-20240403_htm.xml (XML) — 2KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. The following unaudited pro forma balance sheet has been prepared to illustrate the impact of events that followed the close of the Company's year ended December 31, 2023, including (i) the Company's receipt of proceeds from the sale of the securities in private placement transactions that closed on January 31, 2024 and March 13, 2024 and (ii) the sale of real-estate on January 19, 2024. The Company is providing this information to evidence the Company's compliance with the minimum $5 million stockholders' equity requirement for initial listing on The Nasdaq Capital Market. In that regard, the Company believes that as of the date of this Form 8-K, stockholders' equity exceeds $5 million. The unaudited pro forma balance sheet is based on the Company's balance sheet as of December 31, 2023, as contained in the Company's 10-K for the year then ended, filed with the Securities and Exchange Commission on March 22, 2024, adjusted to reflect the subsequent events after the balance sheet date of December 31, 2023, as set out in Note 14 of the 10-K and as described above, as if the events occurred on December 31, 2023. This unaudited pro forma balance sheet is for informational purposes only, and should be read in conjunction with the more detailed audited condensed consolidated financial statements and related notes thereto included in the Company's Form 10-K for the year ended December 31, 2023. The information furnished with this report on Form 8-K, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, and it will not be deemed incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Unaudited Pro Forma Balance Sheet of the Company as of December 31, 2023 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SKYE BIOSCIENCE, INC. Dated: April 3, 2024 /s/ Kaitlyn Arsenault Name: Kaitlyn Arsenault Title: Chief Financial Officer